Companion Animal Diagnostics Market - Global Forecast To 2029
商品番号 : SMB-14821
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年1月 |
| ページ数 | 421 |
| 図表数 | 586 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The companion animal diagnostics market is projected to reach USD 4.55 Billion by 2029 from USD 2.99 Billion in 2024 at a CAGR of 8.8% during the forecast period. Favorable laws and ever-present availability of animal insurance, with more animals getting diagnostics-covered, would greatly contribute to the continued development of this market.
コンパニオンアニマル診断市場は、予測期間中に8.8%のCAGRで2024年の29億9,000万米ドルから2029年までに45億5,000万米ドルに達すると予測されています。有利な法律と動物保険の継続的な利用可能性により、より多くの動物が診断の対象となることが、この市場の継続的な発展に大きく貢献するでしょう。
In countries implementing regulation that forces a higher degree of veterinary expertise, pet owners tend to entrust their animals with doctors and get health check-up diagnostics done periodically. With pet insurance that includes diagnostics availability to a greater percentage of the population than before, due to this access to veterinary care is increased. Insurance companies can now offer plans that can cover diagnostic services like blood tests, imaging, and screenings in order to make it worthwhile to seek timely and preventive care. This trend will ensure healthy pets and further the diagnostic tools and services markets, through which it will provide for further development and growth in demand all over the sector.
“The consumables segment is accounted for the largest share of companion animal diagnostics market.”
The global emergence of veterinary clinics and hospitals with diagnostic facilities has significantly enhanced the demand for consumables used in diagnostics. This has more-than-normal increased the demand for consumables test kits, imaging supplies, and reagents as more veterinary practices are equipped with advanced diagnostics. Superlatively, it is also indicative of a larger trend toward improving healthcare for pets, as pet owners continue to seek better veterinary services for accurate diagnosis of all diseases. On-the-rise number of specialized clinics and hospital businesses offering specific services adds to the use of consumables utilized for routine checkups, disease detection, and disease treatment monitoring. Availability of the most modern diagnostic equipment in veterinary settings not only improves accurate diagnosis, but also promotes regular testings which in turn puts a higher demand on consumables. All these reasons illustrate the strengthening of diagnostic capabilities in veterinary medicine as a potential reason for the continued growth of the overall global market for diagnostic products and services.
“Dogs holds the largest market share of companion animal diagnostics market.”
The rapidly increasing diversity of dog breeds, each having unique genetic predispositions for different health conditions, is increasingly accentuating the need for breed-specific diagnostic tests. With breed-specific care becoming extremely popular among dog owners, so also have the avocations of veterinarians in spotting conditions that are more prevalent in certain breeds. These are a few diseases, including heart disease, hip dysplasia, and certain types of cancers, under which the patient is required to undergo specialized diagnostic techniques for early detection and effective management. Demand for such diagnostic tools and tests to detect these breed-specific phenomena has thereby opened the way for precise and personalized veterinary care. Now possible with improvements in genetic testing, veterinarians can provide more accurate screenings for early intervention and better health outcomes. As dog breeds become more popular, there is bound to be an upsurge for specialty diagnostic service relative to these genetic signs that will further impact the veterinary diagnostics markets.
“North America to witness the substantial growth rate during the forecast period.”
The companion animal diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries based on the region type. In 2023, the Asia Pacific region is projected to exhibit the highest CAGR during the forecast period. However, North America accounts for the largest market share of the companion animal diagnostics market in 2023. Due to increasing incidences of pet health issues such as cancer, diabetes, and kidney diseases, the demand for newer and advanced diagnostic tests will rise to detect and treat these diseases. Most of the pet owners in North America are now seeking quick and reliable diagnostics for better health outcomes for their pets. Some of the larger veterinary infrastructure and rising public interest in pet health have also spurred the use of these “diagnostic tools and technologies.” The availability of ready pet insurance that covers most of the diagnostic services has also increased access to quality care for pet owners. Thus, because the number of pets suffering from chronic and infectious diseases keeps climbing, market demand for companion animal diagnostics will only continue to grow, further bolstering North America’s superiority in the global market.
A breakdown of the primary participants (supply-side) for the companion animal diagnostics market referred to for this report is provided below:
- By Company Type: Tier 1–45%, Tier 2–30%, and Tier 3–25%
- By Designation: C-level–35%, Director Level–25%, and Others–40%
- By Region: North America–40%, Europe–20%, Asia Pacific–25%, Latin America- 10%, and Middle East and Africa– 3% and GCC Countries– 2%
Prominent players in this market include IDEXX (US), Zoetis Services LLC (US), Mars, Incorporated (US), FUJIFILM Corporation (Japan), bioMérieux (France), Thermo Fisher Scientific Inc (US), Virbac (France), Neogen Corporation (US), INDICAL BIOSCIENCE GmbH (Germany), IDvet (France), Randox Laboratories Ltd. (UK), Shenzhen Mindray Animal Medical Technology Co., LTD. (China), Bionote USA Inc. (US), Boule (Sweden), EUROIMMUN Medizinische Labordiagnostika AG (Germany), Biopanda Reagents Ltd (UK), Nova Biomedical (US), Megacor Veterinary Diagnostics (Austria), Eurolyser Diagnostica GmbH (Austria), URIT MEDICAL ELECTRONIC CO., LTD. (China), Fassisi GmbH (Germany), Swissavans AG (Switzerland), Skyla Corporation (Taiwan), Ring Biotechnology Co Ltd (China), and Alvedia (France).
Research Coverage:
The market study covers the companion animal diagnostics market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by product, technology, animal type, application, end user and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
Analysis of Market Dynamics: Drivers (expansion in companion animal population, increasing demand for pet insurance and growing animal health expenditure, growing number of veterinary practitioners) restraints (rising pet care costs) opportunities (growing demand for rapid tests and portable instruments for POC diagnostics, utilization of AI and ML for enhanced disease diagnosis), and challenges (shortage of veterinary practitioners in emerging markets)
- Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new product launches in the companion animal diagnostics market.
- Market Development: Comprehensive information on the lucrative emerging markets, components, demographics, end-user, and region.
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the companion animal diagnostics market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the companion animal diagnostics market like IDEXX (US), Zoetis Services LLC (US), Mars, Incorporated (US), FUJIFILM Corporation (Japan), bioMérieux (France).
Table of Contents
1 INTRODUCTION 35
1.1 STUDY OBJECTIVES 35
1.2 MARKET DEFINITION 35
1.3 MARKET SCOPE 36
1.3.1 MARKETS COVERED & REGIONS CONSIDERED 36
1.3.2 INCLUSIONS & EXCLUSIONS 37
1.3.3 YEARS CONSIDERED 38
1.3.4 CURRENCY CONSIDERED 38
1.4 LIMITATIONS 39
1.5 STAKEHOLDERS 39
1.6 SUMMARY OF CHANGES 39
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
2.1.1 SECONDARY DATA 42
2.1.1.1 Key data from secondary sources 43
2.1.2 PRIMARY DATA 43
2.1.2.1 Key data from primary sources 44
2.1.2.2 Key industry insights 45
2.2 MARKET SIZE ESTIMATION 47
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 52
2.4 MARKET SHARE ESTIMATION 53
2.5 RESEARCH ASSUMPTIONS 53
2.6 RISK ASSESSMENT 53
2.7 RESEARCH LIMITATIONS 53
3 EXECUTIVE SUMMARY 54
4 PREMIUM INSIGHTS 59
4.1 COMPANION ANIMAL DIAGNOSTICS MARKET OVERVIEW 59
4.2 COMPANION ANIMAL DIAGNOSTICS MARKET: REGIONAL MIX 60
4.3 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY & COUNTRY (2023) 61
4.4 COMPANION ANIMAL DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 62
5 MARKET OVERVIEW 63
5.1 INTRODUCTION 63
5.2 MARKET DYNAMICS 63
5.2.1 DRIVERS 64
5.2.1.1 Expansion in companion animal population 64
5.2.1.2 Increasing demand for pet insurance and growth in animal healthcare expenditure 65
5.2.1.3 Growing number of veterinary practitioners 67
5.2.2 RESTRAINTS 68
5.2.2.1 Rising pet care costs 68
5.2.3 OPPORTUNITIES 68
5.2.3.1 Growing demand for rapid tests and portable instruments for POC diagnostics 68
5.2.3.2 Utilization of AI and ML for enhanced disease diagnosis 69
5.2.4 CHALLENGES 69
5.2.4.1 Shortage of veterinary practitioners in emerging markets 69
5.3 INDUSTRY TRENDS 70
5.3.1 ADOPTION OF MULTIPLE TESTING PANELS 70
5.3.2 OUTSOURCING OF VETERINARY DIAGNOSTIC TESTING SERVICES 70
5.4 DISEASE TRENDS 71
5.4.1 ZOONOTIC DISEASES 71
5.4.2 OBESITY & DIABETES 72
5.5 TECHNOLOGICAL ANALYSIS 72
5.5.1 KEY TECHNOLOGIES 72
5.5.1.1 Portable instruments 72
5.5.2 COMPLEMENTARY TECHNOLOGIES 73
5.5.2.1 Wearable health monitoring devices 73
5.5.3 ADJACENT TECHNOLOGIES 73
5.5.3.1 Rapid vet diagnostic kits 73
5.6 TRADE ANALYSIS 73
5.6.1 TRADE ANALYSIS OF MEDICAL DEVICE PRODUCTS (HS CODE 9018) 73
5.6.2 EXPORT DATA FOR COMPANION ANIMAL DIAGNOSTICS CONSUMABLES & INSTRUMENTS (HS CODE 9018) 74
5.6.3 IMPORT DATA FOR COMPANION ANIMAL DIAGNOSTICS CONSUMABLES & INSTRUMENTS (HS CODE 9018) 74
5.7 PRICING ANALYSIS 75
5.7.1 AVERAGE SELLING PRICE OF COMPANION ANIMAL DIAGNOSTICS,
BY KEY PLAYER (2023) 75
5.7.2 AVERAGE SELLING PRICE TREND OF IMMUNODIAGNOSTICS, BY REGION (2021–2023) 76
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
5.9 VALUE CHAIN ANALYSIS 77
5.10 ECOSYSTEM ANALYSIS 78
5.11 PORTER’S FIVE FORCES ANALYSIS 79
5.11.1 THREAT OF NEW ENTRANTS 80
5.11.2 THREAT OF SUBSTITUTES 80
5.11.3 BARGAINING POWER OF SUPPLIERS 81
5.11.4 BARGAINING POWER OF BUYERS 81
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 81
5.12 SUPPLY CHAIN ANALYSIS 81
5.13 REGULATORY ANALYSIS 83
5.13.1 REGULATORY LANDSCAPE 83
5.13.1.1 North America 83
5.13.1.2 Europe 84
5.13.1.3 Asia Pacific 85
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
5.14 PATENT ANALYSIS 87
5.14.1 PATENT PUBLICATION TRENDS FOR COMPANION ANIMAL DIAGNOSTICS 88
5.14.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 88
5.15 KEY CONFERENCES & EVENTS, 2024−2025 90
5.16 KEY STAKEHOLDERS & BUYING CRITERIA 91
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 91
5.16.2 BUYING CRITERIA 91
5.17 CASE STUDY ANALYSIS 92
5.17.1 CASE STUDY 1: OPPORTUNITY ASSESSMENT FOR AUTOMATED IMMUNOASSAY ANALYZERS IN COMPANION ANIMAL IMMUNODIAGNOSTICS 92
5.17.2 CASE STUDY 2: IDENTIFICATION OF INTESTINAL PARASITES IN PET DOGS 93
5.17.3 CASE STUDY 3: INTRODUCTION OF PETLY PLANS BY IDEXX FOR HIGHER VOLUME OF PATIENT VISITS 93
5.18 ADJACENT MARKET ANALYSIS 94
5.18.1 VETERINARY DIAGNOSTICS MARKET 94
5.18.2 VETERINARY REFERENCE LABORATORY MARKET 95
5.19 UNMET NEEDS/END-USER EXPECTATIONS IN COMPANION ANIMAL DIAGNOSTICS MARKET 95
5.20 IMPACT OF AI/GEN AI ON COMPANION ANIMAL DIAGNOSTICS MARKET 96
5.21 INVESTMENT & FUNDING SCENARIO 97
6 COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT 99
6.1 INTRODUCTION 100
6.2 CONSUMABLES 100
6.2.1 GROWING AWARENESS OF PREVENTIVE CARE TO DRIVE MARKET 100
6.3 INSTRUMENTS 101
6.3.1 ADOPTION OF RAPID TESTS FOR INFECTIOUS DISEASE DIAGNOSTICS TO PROPEL MARKET 101
7 COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION 103
7.1 INTRODUCTION 104
7.2 CLINICAL PATHOLOGY 104
7.2.1 INCREASING VOLUME OF CLINICAL TESTS FOR DISEASE DIAGNOSIS TO DRIVE MARKET 104
7.3 BACTERIOLOGY 105
7.3.1 INCREASING PREVALENCE OF ZOONOTIC DISEASES TO DRIVE MARKET 105
7.4 VIROLOGY 106
7.4.1 INCREASING INCIDENCE OF VIRAL OUTBREAKS TO SUPPORT MARKET GROWTH 106
7.5 PARASITOLOGY 107
7.5.1 RISING PREVALENCE OF KENNEL COUGH AND LYME DISEASE TO FUEL UPTAKE 107
7.6 OTHER APPLICATIONS 108
8 COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE 110
8.1 INTRODUCTION 111
8.2 DOGS 112
8.2.1 RISING PET DOG POPULATION TO DRIVE MARKET 112
8.3 CATS 113
8.3.1 GROWING FOCUS ON R&D FOR FELINE CARE TO FUEL UPTAKE 113
8.4 HORSES 115
8.4.1 INCREASING AWARENESS OF EQUINE HEALTH TO SUPPORT MARKET GROWTH 115
8.5 OTHER COMPANION ANIMALS 117
9 COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER 119
9.1 INTRODUCTION 120
9.2 DIAGNOSTIC LABORATORIES 120
9.2.1 INCREASING VOLUME OF SAMPLE TESTS TO DRIVE MARKET 120
9.3 VETERINARY HOSPITALS & CLINICS 122
9.3.1 RISING PET CARE EXPENDITURE TO FUEL MARKET 122
9.4 VETERINARY RESEARCH INSTITUTES & UNIVERSITIES 123
9.4.1 FAVORABLE INDUSTRY-ACADEMIA COLLABORATIONS TO SUPPORT MARKET GROWTH 123
9.5 HOME CARE SETTINGS 125
9.5.1 IMPROVED CARE AND COST EFFICIENCY TO PROPEL MARKET 125
10 COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY 127
10.1 INTRODUCTION 128
10.2 CLINICAL BIOCHEMISTRY 128
10.2.1 CLINICAL CHEMISTRY ANALYSIS 131
10.2.1.1 Reagents, clips, and cartridges 133
10.2.1.1.1 Ability to customize chemistry diagnostic tests to fuel uptake 133
10.2.1.2 Analyzers 134
10.2.1.2.1 Increasing installations of clinical chemistry analyzers to drive market growth 134
10.2.2 GLUCOSE MONITORING 135
10.2.2.1 Blood glucose strips 136
10.2.2.1.1 Growing focus on remote monitoring to drive market 137
10.2.2.2 Glucose monitors 138
10.2.2.2.1 Utilization of portable BGMs to drive market 138
10.2.2.3 Urine glucose strips 140
10.2.2.3.1 Measurement of ketone concentration to drive market 140
10.2.3 BLOOD GAS ELECTROLYTE ANALYSIS 141
10.2.3.1 Reagents, clips, and cartridges 142
10.2.3.1.1 Detection of blood pH to fuel uptake 142
10.2.3.2 Blood gas & electrolyte analyzers 143
10.2.3.2.1 Determination of oxygen and CO2 in blood to boost demand 143
10.3 IMMUNODIAGNOSTICS 145
10.3.1 LATERAL FLOW ASSAYS 148
10.3.1.1 Rapid tests 149
10.3.1.1.1 Increasing prevalence of infectious diseases and real-time monitoring to drive market 149
10.3.1.2 Strip readers 151
10.3.1.2.1 High adoption of in-house testing centers to fuel uptake 151
10.3.2 ELISA TESTS 153
10.3.2.1 High sensitivity to fuel uptake 153
10.3.3 ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS 156
10.3.3.1 Increasing number of allergy cases in pets to support market growth 156
10.3.4 IMMUNOASSAY ANALYZERS 158
10.3.4.1 Ability to handle large number of samples for immunoassay testing to boost demand 158
10.3.5 OTHER IMMUNODIAGNOSTIC PRODUCTS 161
10.4 HEMATOLOGY 162
10.4.1 CARTRIDGES 164
10.4.1.1 Ability to measure hematocrit and hemoglobin levels in blood samples to drive market 164
10.4.2 ANALYZERS 165
10.4.2.1 Complete blood analysis performance evaluation to boost demand 165
10.5 URINALYSIS 167
10.5.1 CLIPS & CARTRIDGES 169
10.5.1.1 Detection of UTIs in cats, dogs, and equine to boost demand 169
10.5.2 URINE ANALYZERS 171
10.5.2.1 Rising technological advancements to support market growth 171
10.5.3 URINE TEST STRIPS 172
10.5.3.1 Qualitative evaluation of leukocytes and protein to drive market 172
10.6 MOLECULAR DIAGNOSTICS 173
10.6.1 PCR TESTS 175
10.6.1.1 Increasing laboratory usage in proteomics & genomics to fuel market 175
10.6.2 MICROARRAYS 177
10.6.2.1 Utilization of biochips in infectious disease diagnostics to support market 177
10.6.3 OTHER MOLECULAR DIAGNOSTICS PRODUCTS 179
10.7 OTHER TECHNOLOGIES 180
11 COMPANION ANIMAL DIAGNOSTICS MARKET, BY REGION 181
11.1 INTRODUCTION 182
11.2 NORTH AMERICA 182
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 183
11.2.2 US 189
11.2.2.1 Rising pet healthcare expenditure to drive market 189
11.2.3 CANADA 195
11.2.3.1 Growing awareness of pet health to propel market 195
11.3 EUROPE 202
11.3.1 ECONOMIC OUTLOOK FOR EUROPE 203
11.3.2 GERMANY 209
11.3.2.1 Growing feline & canine population to drive market 209
11.3.3 UK 215
11.3.3.1 Stable increase in pet ownership and preventive measures against animal diseases to drive market 215
11.3.4 FRANCE 221
11.3.4.1 Technological expertise and innovative advancements in diagnostics to fuel uptake 221
11.3.5 ITALY 227
11.3.5.1 Increased pet adoption and enhanced availability of pet products to support market growth 227
11.3.6 SPAIN 233
11.3.6.1 Rising animal health expenditure and growing number of veterinary facilities to drive market 233
11.3.7 BENELUX 239
11.3.7.1 Increasing pet population in Benelux to fuel uptake 239
11.3.8 REST OF EUROPE 245
11.4 ASIA PACIFIC 250
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 251
11.4.2 CHINA 258
11.4.2.1 Rising cases of zoonotic diseases to drive market 258
11.4.3 JAPAN 265
11.4.3.1 Increasing demand for imported pet breeds to drive market 265
11.4.4 INDIA 270
11.4.4.1 Growth in animal healthcare industry to drive market 270
11.4.5 AUSTRALIA 276
11.4.5.1 Growing focus on pet insurance to boost demand 276
11.4.6 SOUTH KOREA 282
11.4.6.1 Growing focus on animal well-being to boost demand 282
11.4.7 REST OF ASIA PACIFIC 288
11.5 LATIN AMERICA 294
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 295
11.5.2 BRAZIL 300
11.5.2.1 Growth in small animal population to support market 300
11.5.3 MEXICO 306
11.5.3.1 Increasing adoption of advanced diagnostic technologies to fuel uptake 306
11.5.4 REST OF LATIN AMERICA 312
11.6 MIDDLE EAST & AFRICA 318
11.6.1 RELUCTANCE TO SPEND ON PET HEALTH TO RESTRAIN MARKET 318
11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 318
11.7 GCC COUNTRIES 324
11.7.1 INCREASING INCIDENCE OF INFECTIOUS DISEASES IN IMPORTED BREEDS TO SUPPORT MARKET GROWTH 324
11.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 325
12 COMPETITIVE LANDSCAPE 331
12.1 OVERVIEW 331
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 331
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET 332
12.3 REVENUE ANALYSIS, 2019–2023 333
12.4 MARKET SHARE ANALYSIS, 2023 334
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 336
12.5.1 STARS 336
12.5.2 EMERGING LEADERS 336
12.5.3 PERVASIVE PLAYERS 336
12.5.4 PARTICIPANTS 336
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 338
12.5.5.1 Company footprint 338
12.5.5.2 Region footprint 339
12.5.5.3 Technology footprint 340
12.5.5.4 Product footprint 341
12.5.5.5 Animal type footprint 342
12.5.5.6 Application footprint 343
12.5.5.7 End-user footprint 344
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 345
12.6.1 PROGRESSIVE COMPANIES 345
12.6.2 RESPONSIVE COMPANIES 345
12.6.3 DYNAMIC COMPANIES 345
12.6.4 STARTING BLOCKS 345
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 347
12.7 COMPANY VALUATION & FINANCIAL METRICS 348
12.7.1 FINANCIAL METRICS 348
12.7.2 COMPANY VALUATION 349
12.8 BRAND/PRODUCT COMPARISON 350
12.9 R&D EXPENDITURE OF COMPANION ANIMAL DIAGNOSTICS COMPANIES 351
12.10 COMPETITIVE SCENARIO 351
12.10.1 PRODUCT LAUNCHES 351
12.10.2 DEALS 352
12.10.3 EXPANSIONS 353
13 COMPANY PROFILES 354
13.1 KEY PLAYERS 354
13.1.1 IDEXX 354
13.1.1.1 Business overview 354
13.1.1.2 Products offered 355
13.1.1.3 Recent developments 357
13.1.1.3.1 Product launches 357
13.1.1.4 MnM view 357
13.1.1.4.1 Key strengths 357
13.1.1.4.2 Strategic choices 357
13.1.1.4.3 Weaknesses & competitive threats 358
13.1.2 ZOETIS SERVICES LLC 359
13.1.2.1 Business overview 359
13.1.2.2 Products offered 360
13.1.2.3 Recent developments 362
13.1.2.3.1 Product launches 362
13.1.2.3.2 Expansions 362
13.1.2.4 MnM view 363
13.1.2.4.1 Key strengths 363
13.1.2.4.2 Strategic choices 363
13.1.2.4.3 Weaknesses & competitive threats 363
13.1.3 MARS, INCORPORATED 364
13.1.3.1 Business overview 364
13.1.3.2 Products offered 364
13.1.3.3 Recent developments 366
13.1.3.3.1 Deals 366
13.1.3.3.2 Expansions 367
13.1.3.4 MnM view 367
13.1.3.4.1 Key strengths 367
13.1.3.4.2 Strategic choices 368
13.1.3.4.3 Weaknesses & competitive threats 368
13.1.4 BIOMÉRIEUX 369
13.1.4.1 Business overview 369
13.1.4.2 Products offered 370
13.1.4.3 MnM view 371
13.1.4.3.1 Key strengths 371
13.1.4.3.2 Strategic choices 371
13.1.4.3.3 Weaknesses & competitive threats 371
13.1.5 FUJIFILM CORPORATION 372
13.1.5.1 Business overview 372
13.1.5.2 Products offered 373
13.1.5.3 MnM view 374
13.1.5.3.1 Key strengths 374
13.1.5.3.2 Strategic choices 374
13.1.5.3.3 Weaknesses & competitive threats 374
13.1.6 THERMO FISHER SCIENTIFIC INC. 375
13.1.6.1 Business overview 375
13.1.6.2 Products offered 376
13.1.7 NEOGEN CORPORATION 378
13.1.7.1 Business overview 378
13.1.7.2 Products offered 379
13.1.7.3 Recent developments 380
13.1.7.3.1 Deals 380
13.1.8 VIRBAC 381
13.1.8.1 Business overview 381
13.1.8.2 Products offered 382
13.1.9 BOULE 384
13.1.9.1 Business overview 384
13.1.9.2 Products offered 385
13.1.9.3 Recent developments 386
13.1.9.3.1 Product launches 386
13.1.10 INDICAL BIOSCIENCE GMBH 387
13.1.10.1 Business overview 387
13.1.10.2 Products offered 387
13.1.11 IDVET 389
13.1.11.1 Business overview 389
13.1.11.2 Products offered 389
13.1.12 RANDOX LABORATORIES, LTD. 391
13.1.12.1 Business overview 391
13.1.12.2 Products offered 391
13.1.13 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD. 393
13.1.13.1 Business overview 393
13.1.13.2 Products offered 393
13.1.14 BIONOTE USA INC. 394
13.1.14.1 Business overview 394
13.1.14.2 Products offered 394
13.1.14.3 Recent developments 396
13.1.14.3.1 Product launches 396
13.1.14.3.2 Deals 397
13.1.15 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG 398
13.1.15.1 Business overview 398
13.1.15.2 Products offered 398
13.2 OTHER PLAYERS 399
13.2.1 SKYLA CORPORATION 399
13.2.2 EUROLYSER DIAGNOSTICA GMBH 400
13.2.3 NOVA BIOMEDICAL 401
13.2.4 FASSISI GMBH 402
13.2.5 SWISS BIOTECH ASSOCIATION 403
13.2.6 ALVEDIA 404
13.2.7 BIOPANDA REAGENTS LTD. 405
13.2.8 MEGACOR VETERINARY DIAGNOSTICS 406
13.2.9 URIT MEDICAL ELECTRONIC CO., LTD. 407
13.2.10 RING BIOTECHNOLOGY CO., LTD. 408
14 APPENDIX 409
14.1 DISCUSSION GUIDE 409
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 416
14.3 CUSTOMIZATION OPTIONS 418
14.4 RELATED REPORTS 419
14.5 AUTHOR DETAILS 420
LIST OF TABLES
TABLE 1 COMPANION ANIMAL DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS 37
TABLE 2 STANDARD CURRENCY CONVERSION RATES 38
TABLE 3 COMPANION ANIMAL DIAGNOSTICS MARKET: IMPACT ANALYSIS 53
TABLE 4 COMPANION ANIMAL DIAGNOSTIC MARKET: RISK ASSESSMENT ANALYSIS 53
TABLE 5 COMPANION ANIMAL DIAGNOSTICS MARKET: IMPACT ANALYSIS 63
TABLE 6 PET POPULATION, DOGS VS. CATS, 2020–2022 (MILLION) 65
TABLE 7 AVERAGE PREMIUMS PAID IN US, 2020 VS. 2023 66
TABLE 8 NORTH AMERICA: PET HEALTH INSURANCE MARKET, 2012–2023 (USD MILLION) 67
TABLE 9 MULTIPLE TESTING PANELS VS. SINGLE TESTING PANELS 70
TABLE 10 COMMON ZOONOTIC DISEASES TRANSMITTED BY INFECTED COMPANION ANIMALS 71
TABLE 11 POC PORTABLE VETERINARY DIAGNOSTIC INSTRUMENTS 72
TABLE 12 TRADE ANALYSIS OF MEDICAL DEVICE PRODUCTS, 2023 (USD MILLION) 73
TABLE 13 EXPORT DATA FOR COMPANION ANIMAL DIAGNOSTICS CONSUMABLES & INSTRUMENTS (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND) 74
TABLE 14 IMPORT DATA FOR COMPANION ANIMAL DIAGNOSTICS CONSUMABLES & INSTRUMENTS (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND) 74
TABLE 15 AVERAGE SELLING PRICE OF COMPANION ANIMAL DIAGNOSTICS,
BY KEY PLAYER (2023) 75
TABLE 16 AVERAGE SELLING PRICE TREND OF IMMUNODIAGNOSTICS, BY REGION,
2021–2023 (USD) 76
TABLE 17 COMPANION ANIMAL DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 79
TABLE 18 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
TABLE 19 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
TABLE 20 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 21 COMPANION ANIMAL DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 90
TABLE 22 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS 91
TABLE 23 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS 92
TABLE 24 COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 100
TABLE 25 COMPANION ANIMAL DIAGNOSTICS MARKET FOR CONSUMABLES, BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 26 COMPANION ANIMAL DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 27 COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 104
TABLE 28 COMPANION ANIMAL DIAGNOSTICS MARKET FOR CLINICAL PATHOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 29 COMPANION ANIMAL DIAGNOSTICS MARKET FOR BACTERIOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 106
TABLE 30 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VIROLOGY, BY COUNTRY,
2022–2029 (USD MILLION) 107
TABLE 31 COMPANION ANIMAL DIAGNOSTICS MARKET FOR PARASITOLOGY,
BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 32 COMPANION ANIMAL DIAGNOSTICS MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2022–2029 (USD MILLION) 109
TABLE 33 COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2022–2029 (USD MILLION) 111
TABLE 34 DOG POPULATION, BY COUNTRY, 2022–2024 (MILLION) 112
TABLE 35 COMPANION ANIMAL DIAGNOSTICS MARKET FOR DOGS, BY COUNTRY,
2022–2029 (USD MILLION) 113
TABLE 36 CAT POPULATION, BY COUNTRY, 2022−2024 (USD MILLION) 114
TABLE 37 COMPANION ANIMAL DIAGNOSTICS MARKET FOR CATS, BY COUNTRY,
2022–2029 (USD MILLION) 115
TABLE 38 HORSE POPULATION, 2020–2022 116
TABLE 39 COMPANION ANIMAL DIAGNOSTICS MARKET FOR HORSES, BY COUNTRY,
2022–2029 (USD MILLION) 117
TABLE 40 OTHER COMPANION ANIMALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 41 COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 120
TABLE 42 COMPANION ANIMAL DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES,
BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 43 BASIC ANNUAL EXPENSES FOR CATS & DOGS IN US (2024) (USD) 122
TABLE 44 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 45 COMPANION ANIMAL DIAGNOSTICS MARKET FOR VETERINARY RESEARCH INSTITUTES & UNIVERSITIES, BY COUNTRY, 2022–2029 (USD MILLION) 125
TABLE 46 COMPANION ANIMAL DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2029 (USD MILLION) 126
TABLE 47 COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 128
TABLE 48 LIST OF KEY CLINICAL BIOCHEMISTRY PRODUCTS AVAILABLE 129
TABLE 49 CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2022–2029 (USD MILLION) 130
TABLE 50 CLINICAL BIOCHEMISTRY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 51 LIST OF KEY CLINICAL CHEMISTRY ANALYSIS PRODUCTS AVAILABLE 131
TABLE 52 CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 132
TABLE 53 CLINICAL CHEMISTRY ANALYSIS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 132
TABLE 54 CLINICAL CHEMISTRY REAGENTS, CLIPS, AND CARTRIDGES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 55 CLINICAL CHEMISTRY ANALYZERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 134
TABLE 56 CLINICAL CHEMISTRY ANALYZERS MARKET, BY REGION,
2022–2029 (THOUSAND UNITS) 135
TABLE 57 LIST OF KEY GLUCOSE MONITORING PRODUCTS AVAILABLE 135
TABLE 58 GLUCOSE MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 136
TABLE 59 GLUCOSE MONITORING MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 60 BLOOD GLUCOSE STRIPS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 61 GLUCOSE MONITORS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 62 GLUCOSE MONITORS MARKET, BY COUNTRY, 2022–2029 (THOUSAND UNITS) 139
TABLE 63 LIST OF KEY URINE GLUCOSE STRIPS AVAILABLE 140
TABLE 64 URINE GLUCOSE STRIPS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 65 BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 141
TABLE 66 BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 142
TABLE 67 BLOOD GAS ELECTROLYTE REAGENTS, CLIPS, AND CARTRIDGES MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 68 BLOOD GAS & ELECTROLYTE ANALYZERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 144
TABLE 69 BLOOD GAS & ELECTROLYTE ANALYZERS MARKET, BY COUNTRY,
2022–2029 (THOUSAND UNITS) 145
TABLE 70 LIST OF KEY IMMUNODIAGNOSTIC PRODUCTS AVAILABLE 146
TABLE 71 IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 147
TABLE 72 IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 73 LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 148
TABLE 74 LATERAL FLOW ASSAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 75 LATERAL FLOW KITS: ADVANTAGES & DISADVANTAGES 150
TABLE 76 LIST OF KEY LATERAL TEST KITS AVAILABLE 150
TABLE 77 LATERAL FLOW RAPID TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 151
TABLE 78 LATERAL FLOW STRIP READERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 152
TABLE 79 ELISA: ADVANTAGES & DISADVANTAGES 153
TABLE 80 LIST OF KEY ELISA TEST KITS AVAILABLE 154
TABLE 81 ELISA TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 82 ELISA TESTS MARKET, BY REGION, 2022–2029 (THOUSAND UNITS) 156
TABLE 83 LIST OF KEY ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC KITS AVAILABLE 157
TABLE 84 ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 157
TABLE 85 ALLERGEN-SPECIFIC IMMUNODIAGNOSTIC TESTS MARKET, BY COUNTRY,
2022–2029 (THOUSAND UNITS) 158
TABLE 86 LIST OF KEY IMMUNOASSAY ANALYZERS AVAILABLE 159
TABLE 87 IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 88 IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY,
2022–2029 (THOUSAND UNITS) 161
TABLE 89 LIST OF KEY IMMUNOASSAY REAGENTS & CONSUMABLES AVAILABLE 161
TABLE 90 OTHER IMMUNODIAGNOSTIC PRODUCTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 162
TABLE 91 LIST OF KEY HEMATOLOGY PRODUCTS AVAILABLE 163
TABLE 92 HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 163
TABLE 93 HEMATOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 164
TABLE 94 HEMATOLOGY CARTRIDGES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 165
TABLE 95 HEMATOLOGY ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 166
TABLE 96 HEMATOLOGY ANALYZERS MARKET, BY COUNTRY,
2022–2029 (THOUSAND UNITS) 167
TABLE 97 LIST OF KEY URINALYSIS PRODUCTS AVAILABLE 167
TABLE 98 URINALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 168
TABLE 99 URINALYSIS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 169
TABLE 100 LIST OF KEY CLIPS & CARTRIDGES AVAILABLE 170
TABLE 101 URINALYSIS CLIPS & CARTRIDGES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 170
TABLE 102 URINE ANALYZERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 103 URINE ANALYZERS MARKET, BY REGION, 2022–2029 (THOUSAND UNITS) 172
TABLE 104 URINE TEST STRIPS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 105 MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 174
TABLE 106 MOLECULAR DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 107 LIST OF KEY PCR TESTS AVAILABLE 175
TABLE 108 PCR TESTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 176
TABLE 109 PCR TESTS MARKET, BY REGION, 2022–2029 (THOUSAND UNITS) 176
TABLE 110 LIST OF KEY MICROARRAY TESTS AVAILABLE 177
TABLE 111 MICROARRAYS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 178
TABLE 112 MICROARRAYS MARKET, BY REGION, 2022–2029 (USD MILLION) 178
TABLE 113 OTHER MOLECULAR DIAGNOSTICS PRODUCTS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 179
TABLE 114 OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 180
TABLE 115 COMPANION ANIMAL DIAGNOSTICS MARKET, BY REGION,
2022–2029 (USD MILLION) 182
TABLE 116 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 184
TABLE 117 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 184
TABLE 118 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 184
TABLE 119 NORTH AMERICA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 185
TABLE 120 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 185
TABLE 121 NORTH AMERICA: CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2022–2029 (USD MILLION) 186
TABLE 122 NORTH AMERICA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 186
TABLE 123 NORTH AMERICA: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 186
TABLE 124 NORTH AMERICA: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 187
TABLE 125 NORTH AMERICA: HEMATOLOGY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 187
TABLE 126 NORTH AMERICA: URINANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 187
TABLE 127 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 188
TABLE 128 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 188
TABLE 129 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 189
TABLE 130 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY END USER, 2022–2029 (USD MILLION) 189
TABLE 131 US: KEY MACROINDICATORS 190
TABLE 132 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 190
TABLE 133 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 191
TABLE 134 US: IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 191
TABLE 135 US: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 192
TABLE 136 US: CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2022–2029 (USD MILLION) 192
TABLE 137 US: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 192
TABLE 138 US: GLUCOSE MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 193
TABLE 139 US: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 193
TABLE 140 US: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 193
TABLE 141 US: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 194
TABLE 142 US: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 194
TABLE 143 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2022–2029 (USD MILLION) 194
TABLE 144 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 195
TABLE 145 US: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 195
TABLE 146 CANADA: KEY MACROINDICATORS 196
TABLE 147 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 196
TABLE 148 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 197
TABLE 149 CANADA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 197
TABLE 150 CANADA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 198
TABLE 151 CANADA: CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 152 CANADA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 198
TABLE 153 CANADA: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 199
TABLE 154 CANADA: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 199
TABLE 155 CANADA: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 199
TABLE 156 CANADA: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 200
TABLE 157 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 200
TABLE 158 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2022–2029 (USD MILLION) 200
TABLE 159 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 201
TABLE 160 CANADA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 201
TABLE 161 EUROPE: COMPANION ANIMAL POPULATION, 2022 (MILLION) 203
TABLE 162 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 204
TABLE 163 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 204
TABLE 164 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 205
TABLE 165 EUROPE: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 205
TABLE 166 EUROPE: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 206
TABLE 167 EUROPE: CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 168 EUROPE: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 206
TABLE 169 EUROPE: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 207
TABLE 170 EUROPE: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 207
TABLE 171 EUROPE: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 207
TABLE 172 EUROPE: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 208
TABLE 173 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 208
TABLE 174 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2022–2029 (USD MILLION) 208
TABLE 175 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 209
TABLE 176 EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 209
TABLE 177 GERMANY: KEY MACROINDICATORS 210
TABLE 178 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 210
TABLE 179 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 210
TABLE 180 GERMANY: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 211
TABLE 181 GERMANY: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 211
TABLE 182 GERMANY: CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2022–2029 (USD MILLION) 211
TABLE 183 GERMANY: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 212
TABLE 184 GERMANY: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 212
TABLE 185 GERMANY: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 212
TABLE 186 GERMANY: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 213
TABLE 187 GERMANY: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 213
TABLE 188 GERMANY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 213
TABLE 189 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2022–2029 (USD MILLION) 214
TABLE 190 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 214
TABLE 191 GERMANY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 215
TABLE 192 UK: HOUSEHOLDS WITH PETS (2022) 216
TABLE 193 UK: KEY MACROINDICATORS 216
TABLE 194 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 216
TABLE 195 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 217
TABLE 196 UK: IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 217
TABLE 197 UK: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 218
TABLE 198 UK: CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2022–2029 (USD MILLION) 218
TABLE 199 UK: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 218
TABLE 200 UK: GLUCOSE MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 219
TABLE 201 UK: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 219
TABLE 202 UK: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 219
TABLE 203 UK: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 220
TABLE 204 UK: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 220
TABLE 205 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2022–2029 (USD MILLION) 220
TABLE 206 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 221
TABLE 207 UK: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 221
TABLE 208 FRANCE: KEY MACROINDICATORS 222
TABLE 209 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 222
TABLE 210 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 223
TABLE 211 FRANCE: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 223
TABLE 212 FRANCE: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 224
TABLE 213 FRANCE: CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2022–2029 (USD MILLION) 224
TABLE 214 FRANCE: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 224
TABLE 215 FRANCE: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 225
TABLE 216 FRANCE: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 225
TABLE 217 FRANCE: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 225
TABLE 218 FRANCE: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 226
TABLE 219 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 226
TABLE 220 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2022–2029 (USD MILLION) 226
TABLE 221 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 227
TABLE 222 FRANCE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 227
TABLE 223 ITALY: KEY MACROINDICATORS 228
TABLE 224 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 228
TABLE 225 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 228
TABLE 226 ITALY: IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 229
TABLE 227 ITALY: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 229
TABLE 228 ITALY: CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2022–2029 (USD MILLION) 229
TABLE 229 ITALY: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 230
TABLE 230 ITALY: GLUCOSE MONITORING MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 230
TABLE 231 ITALY: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 230
TABLE 232 ITALY: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 231
TABLE 233 ITALY: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 231
TABLE 234 ITALY: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 231
TABLE 235 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2022–2029 (USD MILLION) 232
TABLE 236 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 232
TABLE 237 ITALY: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 233
TABLE 238 SPAIN: KEY MACROINDICATORS 233
TABLE 239 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 234
TABLE 240 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 234
TABLE 241 SPAIN: IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 235
TABLE 242 SPAIN: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 235
TABLE 243 SPAIN: CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 244 SPAIN: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 236
TABLE 245 SPAIN: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 236
TABLE 246 SPAIN: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 237
TABLE 247 SPAIN: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 237
TABLE 248 SPAIN: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 237
TABLE 249 SPAIN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 238
TABLE 250 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2022–2029 (USD MILLION) 238
TABLE 251 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 239
TABLE 252 SPAIN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 239
TABLE 253 BENELUX: KEY MACROINDICATORS 240
TABLE 254 BENELUX: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 240
TABLE 255 BENELUX: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 240
TABLE 256 BENELUX: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 241
TABLE 257 BENELUX: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 241
TABLE 258 BENELUX: CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2022–2029 (USD MILLION) 241
TABLE 259 BENELUX: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 242
TABLE 260 BENELUX: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 242
TABLE 261 BENELUX: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 242
TABLE 262 BENELUX: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 243
TABLE 263 BENELUX: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 243
TABLE 264 BENELUX: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 243
TABLE 265 BENELUX: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2022–2029 (USD MILLION) 244
TABLE 266 BENELUX: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 244
TABLE 267 BENELUX: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 245
TABLE 268 REST OF EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 245
TABLE 269 REST OF EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 246
TABLE 270 REST OF EUROPE: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 246
TABLE 271 REST OF EUROPE: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 247
TABLE 272 REST OF EUROPE: CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2022–2029 (USD MILLION) 247
TABLE 273 REST OF EUROPE: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 247
TABLE 274 REST OF EUROPE: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 248
TABLE 275 REST OF EUROPE: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 248
TABLE 276 REST OF EUROPE: HEMATOLOGY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 248
TABLE 277 REST OF EUROPE: URINANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 249
TABLE 278 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 249
TABLE 279 REST OF EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 249
TABLE 280 REST OF EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 250
TABLE 281 REST OF EUROPE: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 250
TABLE 282 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 253
TABLE 283 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 253
TABLE 284 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 254
TABLE 285 ASIA PACIFIC: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 254
TABLE 286 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 255
TABLE 287 ASIA PACIFIC: CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2022–2029 (USD MILLION) 255
TABLE 288 ASIA PACIFIC: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 255
TABLE 289 ASIA PACIFIC: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 256
TABLE 290 ASIA PACIFIC: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 256
TABLE 291 ASIA PACIFIC: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 256
TABLE 292 ASIA PACIFIC: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 257
TABLE 293 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 257
TABLE 294 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 257
TABLE 295 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 258
TABLE 296 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 258
TABLE 297 CHINA: KEY MACROINDICATORS 259
TABLE 298 CHINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 259
TABLE 299 CHINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 260
TABLE 300 CHINA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 260
TABLE 301 CHINA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 261
TABLE 302 CHINA: CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2022–2029 (USD MILLION) 261
TABLE 303 CHINA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 261
TABLE 304 CHINA: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 262
TABLE 305 CHINA: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 262
TABLE 306 CHINA: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 262
TABLE 307 CHINA: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 263
TABLE 308 CHINA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 263
TABLE 309 CHINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2022–2029 (USD MILLION) 263
TABLE 310 CHINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 264
TABLE 311 CHINA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 264
TABLE 312 JAPAN: KEY MACROINDICATORS 265
TABLE 313 JAPAN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 265
TABLE 314 JAPAN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 266
TABLE 315 JAPAN: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 266
TABLE 316 JAPAN: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 267
TABLE 317 JAPAN: CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2022–2029 (USD MILLION) 267
TABLE 318 JAPAN: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 267
TABLE 319 JAPAN: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 268
TABLE 320 JAPAN: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 268
TABLE 321 JAPAN: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 268
TABLE 322 JAPAN: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 269
TABLE 323 JAPAN: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 269
TABLE 324 JAPAN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2022–2029 (USD MILLION) 269
TABLE 325 JAPAN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 270
TABLE 326 JAPAN: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 270
TABLE 327 INDIA: KEY MACROINDICATORS 271
TABLE 328 INDIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 271
TABLE 329 INDIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 271
TABLE 330 INDIA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 272
TABLE 331 INDIA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 272
TABLE 332 INDIA: CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2022–2029 (USD MILLION) 273
TABLE 333 INDIA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 273
TABLE 334 INDIA: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 273
TABLE 335 INDIA: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 274
TABLE 336 INDIA: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 274
TABLE 337 INDIA: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 274
TABLE 338 INDIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 275
TABLE 339 INDIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2022–2029 (USD MILLION) 275
TABLE 340 INDIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2
022–2029 (USD MILLION) 276
TABLE 341 INDIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 276
TABLE 342 AUSTRALIA: KEY MACROINDICATORS 277
TABLE 343 AUSTRALIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 277
TABLE 344 AUSTRALIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 277
TABLE 345 AUSTRALIA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 278
TABLE 346 AUSTRALIA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 278
TABLE 347 AUSTRALIA: CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2022–2029 (USD MILLION) 279
TABLE 348 AUSTRALIA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 279
TABLE 349 AUSTRALIA: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 279
TABLE 350 AUSTRALIA: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 280
TABLE 351 AUSTRALIA: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 280
TABLE 352 AUSTRALIA: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 280
TABLE 353 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 281
TABLE 354 AUSTRALIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 281
TABLE 355 AUSTRALIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 282
TABLE 356 AUSTRALIA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 282
TABLE 357 SOUTH KOREA: KEY MACROINDICATORS 283
TABLE 358 SOUTH KOREA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 283
TABLE 359 SOUTH KOREA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 283
TABLE 360 SOUTH KOREA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 284
TABLE 361 SOUTH KOREA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 284
TABLE 362 SOUTH KOREA: CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2022–2029 (USD MILLION) 285
TABLE 363 SOUTH KOREA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 285
TABLE 364 SOUTH KOREA: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 285
TABLE 365 SOUTH KOREA: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 286
TABLE 366 SOUTH KOREA: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 286
TABLE 367 SOUTH KOREA: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 286
TABLE 368 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 287
TABLE 369 SOUTH KOREA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 287
TABLE 370 SOUTH KOREA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 288
TABLE 371 SOUTH KOREA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 288
TABLE 372 REST OF ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 289
TABLE 373 REST OF ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 289
TABLE 374 REST OF ASIA PACIFIC: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 290
TABLE 375 REST OF ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 290
TABLE 376 REST OF ASIA PACIFIC: CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2022–2029 (USD MILLION) 291
TABLE 377 REST OF ASIA PACIFIC: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 291
TABLE 378 REST OF ASIA PACIFIC: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 291
TABLE 379 REST OF ASIA PACIFIC: BLOOD GAS ELECTROLYTE ANALYSIS MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 292
TABLE 380 REST OF ASIA PACIFIC: HEMATOLOGY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 292
TABLE 381 REST OF ASIA PACIFIC: URINANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 292
TABLE 382 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 293
TABLE 383 REST OF ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY ANIMAL TYPE, 2022–2029 (USD MILLION) 293
TABLE 384 REST OF ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 294
TABLE 385 REST OF ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY END USER, 2022–2029 (USD MILLION) 294
TABLE 386 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 295
TABLE 387 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 295
TABLE 388 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 296
TABLE 389 LATIN AMERICA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 296
TABLE 390 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 297
TABLE 391 LATIN AMERICA: CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2022–2029 (USD MILLION) 297
TABLE 392 LATIN AMERICA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 297
TABLE 393 LATIN AMERICA: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 298
TABLE 394 LATIN AMERICA: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 298
TABLE 395 LATIN AMERICA: HEMATOLOGY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 298
TABLE 396 LATIN AMERICA: URINANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 299
TABLE 397 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 299
TABLE 398 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 299
TABLE 399 LATIN AMERICA COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 300
TABLE 400 LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 300
TABLE 401 BRAZIL: KEY MACROINDICATORS 301
TABLE 402 BRAZIL: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 301
TABLE 403 BRAZIL: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 301
TABLE 404 BRAZIL: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 302
TABLE 405 BRAZIL: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 302
TABLE 406 BRAZIL: CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2022–2029 (USD MILLION) 302
TABLE 407 BRAZIL: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 303
TABLE 408 BRAZIL: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 303
TABLE 409 BRAZIL: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 303
TABLE 410 BRAZIL: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 304
TABLE 411 BRAZIL: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 304
TABLE 412 BRAZIL: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 304
TABLE 413 BRAZIL: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2022–2029 (USD MILLION) 305
TABLE 414 BRAZIL: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 305
TABLE 415 BRAZIL: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 306
TABLE 416 MEXICO: KEY MACROINDICATORS 307
TABLE 417 MEXICO: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 307
TABLE 418 MEXICO: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2022–2029 (USD MILLION) 307
TABLE 419 MEXICO: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 308
TABLE 420 MEXICO: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 308
TABLE 421 MEXICO: CLINICAL BIOCHEMISTRY MARKET, BY TYPE, 2022–2029 (USD MILLION) 308
TABLE 422 MEXICO: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 309
TABLE 423 MEXICO: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 309
TABLE 424 MEXICO: BLOOD GAS ELECTROLYTE ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 309
TABLE 425 MEXICO: HEMATOLOGY MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 310
TABLE 426 MEXICO: URINANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 310
TABLE 427 MEXICO: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 310
TABLE 428 MEXICO: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2022–2029 (USD MILLION) 311
TABLE 429 MEXICO: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 311
TABLE 430 MEXICO: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2022–2029 (USD MILLION) 312
TABLE 431 REST OF LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 312
TABLE 432 REST OF LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 313
TABLE 433 REST OF LATIN AMERICA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 313
TABLE 434 REST OF LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 314
TABLE 435 REST OF LATIN AMERICA: CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2022–2029 (USD MILLION) 314
TABLE 436 REST OF LATIN AMERICA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 314
TABLE 437 REST OF LATIN AMERICA: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 315
TABLE 438 REST OF LATIN AMERICA: BLOOD GAS ELECTROLYTE ANALYSIS MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 315
TABLE 439 REST OF LATIN AMERICA: HEMATOLOGY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 315
TABLE 440 REST OF LATIN AMERICA: URINANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 316
TABLE 441 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 316
TABLE 442 REST OF LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY ANIMAL TYPE, 2022–2029 (USD MILLION) 316
TABLE 443 REST OF LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 317
TABLE 444 REST OF LATIN AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY END USER, 2022–2029 (USD MILLION) 317
TABLE 445 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 319
TABLE 446 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY TECHNOLOGY, 2022–2029 (USD MILLION) 319
TABLE 447 MIDDLE EAST & AFRICA: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 320
TABLE 448 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 320
TABLE 449 MIDDLE EAST & AFRICA: CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2022–2029 (USD MILLION) 321
TABLE 450 MIDDLE EAST & AFRICA: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 321
TABLE 451 MIDDLE EAST & AFRICA: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 321
TABLE 452 MIDDLE EAST & AFRICA: BLOOD GAS ELECTROLYTE ANALYSIS MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 322
TABLE 453 MIDDLE EAST & AFRICA: HEMATOLOGY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 322
TABLE 454 MIDDLE EAST & AFRICA: URINANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 322
TABLE 455 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 323
TABLE 456 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY ANIMAL TYPE, 2022–2029 (USD MILLION) 323
TABLE 457 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 324
TABLE 458 MIDDLE EAST & AFRICA: COMPANION ANIMAL DIAGNOSTICS MARKET,
BY END USER, 2022–2029 (USD MILLION) 324
TABLE 459 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 325
TABLE 460 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION) 326
TABLE 461 GCC COUNTRIES: IMMUNODIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 326
TABLE 462 GCC COUNTRIES: LATERAL FLOW ASSAYS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 327
TABLE 463 GCC COUNTRIES: CLINICAL BIOCHEMISTRY MARKET, BY TYPE,
2022–2029 (USD MILLION) 327
TABLE 464 GCC COUNTRIES: CLINICAL CHEMISTRY ANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 327
TABLE 465 GCC COUNTRIES: GLUCOSE MONITORING MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 328
TABLE 466 GCC COUNTRIES: BLOOD GAS ELECTROLYTE ANALYSIS MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 328
TABLE 467 GCC COUNTRIES: HEMATOLOGY MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 328
TABLE 468 GCC COUNTRIES: URINANALYSIS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 329
TABLE 469 GCC COUNTRIES: MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 329
TABLE 470 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE, 2022–2029 (USD MILLION) 329
TABLE 471 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 330
TABLE 472 GCC COUNTRIES: COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 330
TABLE 473 COMPANION ANIMAL DIAGNOSTICS MARKET: DEGREE OF COMPETITION 334
TABLE 474 COMPANION ANIMAL DIAGNOSTICS MARKET: REGION FOOTPRINT 339
TABLE 475 COMPANION ANIMAL DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT 340
TABLE 476 COMPANION ANIMAL DIAGNOSTICS MARKET: PRODUCT FOOTPRINT 341
TABLE 477 COMPANION ANIMAL DIAGNOSTICS MARKET: ANIMAL TYPE FOOTPRINT 342
TABLE 478 COMPANION ANIMAL DIAGNOSTICS MARKET: APPLICATION FOOTPRINT 343
TABLE 479 COMPANION ANIMAL DIAGNOSTICS MARKET: END-USER FOOTPRINT 344
TABLE 480 COMPANION ANIMAL DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUP/ SME PLAYERS 347
TABLE 481 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS 347
TABLE 482 COMPANION ANIMAL DIAGNOSTICS MARKET: PRODUCT LAUNCHES
(JANUARY 2021−NOVEMBER 2024) 351
TABLE 483 COMPANION ANIMAL DIAGNOSTICS MARKET: DEALS (JANUARY 2021–
NOVEMBER 2024) 352
TABLE 484 COMPANION ANIMAL DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021– NOVEMBER 2024 353
TABLE 485 IDEXX: COMPANY OVERVIEW 354
TABLE 486 IDEXX: PRODUCTS OFFERED 355
TABLE 487 IDEXX: PRODUCT LAUNCHES, JANUARY 2021–NOVEMBER 2024 357
TABLE 488 ZOETIS SERVICES LLC: COMPANY OVERVIEW 359
TABLE 489 ZOETIS SERVICES LLC: PRODUCTS OFFERED 360
TABLE 490 ZOETIS SERVICES LLC: PRODUCT LAUNCHES, JANUARY 2021–NOVEMBER 2024 362
TABLE 491 ZOETIS SERVICES LLC.: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 362
TABLE 492 MARS, INCORPORATED: COMPANY OVERVIEW 364
TABLE 493 MARS, INCORPORATED: PRODUCTS OFFERED 364
TABLE 494 MARS, INCORPORATED: DEALS, JANUARY 2021–NOVEMBER 2024 366
TABLE 495 MARS, INCORPORATED: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 367
TABLE 496 BIOMÉRIEUX: COMPANY OVERVIEW 369
TABLE 497 BIOMÉRIEUX: PRODUCTS OFFERED 370
TABLE 498 FUJIFILM CORPORATION: COMPANY OVERVIEW 372
TABLE 499 FUJIFILM CORPORATION: PRODUCTS OFFERED 373
TABLE 500 FUJIFILM CORPORATION: DEALS, JANUARY 2021–NOVEMBER 2024 374
TABLE 501 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 375
TABLE 502 THERMO FISHER SCIENTIFIC INC: PRODUCTS OFFERED 376
TABLE 503 NEOGEN CORPORATION: COMPANY OVERVIEW 378
TABLE 504 NEOGEN CORPORATION: PRODUCTS OFFERED 379
TABLE 505 NEOGEN CORPORATION: DEALS, JANUARY 2021–NOVEMBER 2024 380
TABLE 506 VIRBAC: COMPANY OVERVIEW 381
TABLE 507 VIRBAC: PRODUCTS OFFERED 382
TABLE 508 BOULE: COMPANY OVERVIEW 384
TABLE 509 BOULE: PRODUCTS OFFERED 385
TABLE 510 BOULE: PRODUCT LAUNCHES, JANUARY 2021–NOVEMBER 2024 386
TABLE 511 BOULE: DEALS, JANUARY 2021–NOVEMBER 2024 386
TABLE 512 INDICAL BIOSCIENCE GMBH: COMPANY OVERVIEW 387
TABLE 513 INDICAL BIOSCIENCE GMBH: PRODUCTS OFFERED 387
TABLE 514 IDVET: COMPANY OVERVIEW 389
TABLE 515 IDVET: PRODUCTS OFFERED 389
TABLE 516 RANDOX LABORATORIES, LTD.: COMPANY OVERVIEW 391
TABLE 517 RANDOX LABORATORIES, LTD.: PRODUCTS OFFERED 391
TABLE 518 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW 393
TABLE 519 SHENZHEN MINDRAY ANIMAL MEDICAL TECHNOLOGY CO., LTD.:
PRODUCTS OFFERED 393
TABLE 520 BIONOTE USA INC.: COMPANY OVERVIEW 394
TABLE 521 BIONOTE USA INC: PRODUCTS OFFERED 394
TABLE 522 BIONOTE USA INC.: PRODUCT LAUNCHES, JANUARY 2021–NOVEMBER 2024 396
TABLE 523 BIONOTE USA INC.: DEALS, JANUARY 2021–NOVEMBER 2024 397
TABLE 524 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: COMPANY OVERVIEW 398
TABLE 525 EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG: PRODUCTS OFFERED 398
LIST OF FIGURES
FIGURE 1 COMPANION ANIMAL DIAGNOSTICS MARKET: MARKETS COVERED &
REGIONS CONSIDERED 36
FIGURE 2 RESEARCH DESIGN 41
FIGURE 3 PRIMARY SOURCES 43
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS 45
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE PARTICIPANTS,
BY COMPANY TYPE, DESIGNATION, AND REGION 46
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: DEMAND SIDE PARTICIPANTS,
BY END USER, DESIGNATION, AND REGION 46
FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: IDEXX LABORATORIES, INC. 48
FIGURE 8 SUPPLY SIDE ANALYSIS OF LEADING COMPANIES (2023) 48
FIGURE 9 CAGR PROJECTIONS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF COMPANION ANIMAL DIAGNOSTICS MARKET (2024–2029) 50
FIGURE 10 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS 50
FIGURE 11 TOP-DOWN APPROACH 51
FIGURE 12 MARKET DATA TRIANGULATION METHODOLOGY 52
FIGURE 13 COMPANION ANIMAL DIAGNOSTICS MARKET, BY PRODUCT,
2024 VS. 2029 (USD MILLION) 54
FIGURE 14 COMPANION ANIMAL DIAGNOSTICS MARKET, BY TECHNOLOGY,
2024 VS. 2029 (USD MILLION) 55
FIGURE 15 COMPANION ANIMAL DIAGNOSTICS MARKET, BY APPLICATION,
2024 VS. 2029 (USD MILLION) 55
FIGURE 16 COMPANION ANIMAL DIAGNOSTICS MARKET, BY ANIMAL TYPE,
2024 VS. 2029 (USD MILLION) 56
FIGURE 17 COMPANION ANIMAL DIAGNOSTICS MARKET, BY END USER,
2024 VS. 2029 (USD MILLION) 57
FIGURE 18 GEOGRAPHIC SNAPSHOT: COMPANION ANIMAL DIAGNOSTICS MARKET 58
FIGURE 19 GROWING COMPANION ANIMAL POPULATION TO PROPEL MARKET 59
FIGURE 20 ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 60
FIGURE 21 CLINICAL CHEMISTRY SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE
IN CHINA IN 2023 61
FIGURE 22 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD 62
FIGURE 23 COMPANION ANIMAL DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64
FIGURE 24 US: PET EXPENDITURE, DOGS VS CATS, 2024 (USD) 66
FIGURE 25 AVERAGE SELLING PRICE TREND OF IMMUNODIAGNOSTICS,
BY REGION (2021–2023) 76
FIGURE 26 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 77
FIGURE 27 COMPANION ANIMAL DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 78
FIGURE 28 COMPANION ANIMAL DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 78
FIGURE 29 COMPANION ANIMAL DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 79
FIGURE 30 COMPANION ANIMAL DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 83
FIGURE 31 PATENT PUBLICATION TRENDS (2014–APRIL 2024) 88
FIGURE 32 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL DIAGNOSTICS DIAGNOSTIC PATENTS (JANUARY 2014–DECEMBER 2024) 89
FIGURE 33 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 APPLICATIONS 91
FIGURE 34 KEY BUYING CRITERIA FOR TOP 3 APPLICATIONS 91
FIGURE 35 VETERINARY DIAGNOSTICS MARKET OVERVIEW 94
FIGURE 36 VETERINARY REFERENCE LABORATORY MARKET OVERVIEW 95
FIGURE 37 IMPACT OF AI/GEN AI ON COMPANION ANIMAL DIAGNOSTICS MARKET 97
FIGURE 38 NUMBER OF DEALS & FUNDS IN COMPANION ANIMAL DIAGNOSTICS MARKET, 2018–2022 (USD MILLION) 98
FIGURE 39 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2018–2022 98
FIGURE 40 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2018–2022 (USD MILLION) 98
FIGURE 41 CORNELL UNIVERSITY: SPONSORED RESEARCH & DIRECT COST EXPENSES BETWEEN FY 2019−FY 2023 (USD MILLION) 124
FIGURE 42 NORTH AMERICA: COMPANION ANIMAL DIAGNOSTICS MARKET SNAPSHOT 183
FIGURE 43 ASIA PACIFIC: COMPANION ANIMAL DIAGNOSTICS MARKET SNAPSHOT 252
FIGURE 44 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PRODUCT COMPANIES 332
FIGURE 45 REVENUE ANALYSIS OF KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET (2019–2023) 333
FIGURE 46 MARKET SHARE ANALYSIS OF KEY PLAYERS IN COMPANION ANIMAL DIAGNOSTICS MARKET (2023) 334
FIGURE 47 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 337
FIGURE 48 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPANY FOOTPRINT 338
FIGURE 49 COMPANION ANIMAL DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 346
FIGURE 50 EV/EBITDA OF KEY VENDORS 348
FIGURE 51 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS 349
FIGURE 52 BRAND/PRODUCT COMPARATIVE ANALYSIS 350
FIGURE 53 R&D EXPENDITURE OF KEY PLAYERS (2022 VS. 2023) 351
FIGURE 54 IDEXX: COMPANY SNAPSHOT (2023) 355
FIGURE 55 ZOETIS SERVICES LLC: COMPANY SNAPSHOT (2023) 360
FIGURE 56 BIOMÉRIEUX: COMPANY SNAPSHOT (2023) 370
FIGURE 57 FUJIFILM CORPORATION: COMPANY SNAPSHOT (2023) 373
FIGURE 58 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023) 376
FIGURE 59 NEOGEN CORPORATION: COMPANY SNAPSHOT (2024) 379
FIGURE 60 VIRBAC: COMPANY SNAPSHOT (2024) 382
FIGURE 61 BOULE: COMPANY SNAPSHOT (2023) 385
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11